| Revision as of 07:14, 1 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or bugs)← Previous edit | Revision as of 22:55, 18 November 2011 edit undo86.30.243.179 (talk) added original patentNext edit → | ||
| Line 1: | Line 1: | ||
| {{ |
{{Refimprove|date=November 2011}} | ||
| {{Drugbox | {{Drugbox | ||
| Line 52: | Line 52: | ||
| }} | }} | ||
| '''Isoaminile''' ('''Peracon''') |
'''Isoaminile''' was discovered by Hoechst AG in the 1950s<ref>DE Patent 1034649</ref>. It is used under the trade0anme ('''Peracon''') as an ] and is structurally related to ]. ] effects have been noted from doses approximately 300 mg and above. The normal therapeutic dose is 40-80 mg of the cyclamate salt not to exceed five doses in a 24-hour period. In addition to central antitussive effects it is also an ], exhibiting both ] and ] actions. | ||
Revision as of 22:55, 18 November 2011
 | This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Isoaminile" – news · newspapers · books · scholar · JSTOR (November 2011) (Learn how and when to remove this message) |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.940  |
| Chemical and physical data | |
| Formula | C16H24N2 |
| Molar mass | 244.375 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Isoaminile was discovered by Hoechst AG in the 1950s. It is used under the trade0anme (Peracon) as an antitussive and is structurally related to methadone. Psychedelic effects have been noted from doses approximately 300 mg and above. The normal therapeutic dose is 40-80 mg of the cyclamate salt not to exceed five doses in a 24-hour period. In addition to central antitussive effects it is also an anticholinergic, exhibiting both antimuscarinic and antinicotinic actions.
References
- DE Patent 1034649
| Hallucinogens | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 | This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it. |
 | This hallucinogen-related article is a stub. You can help Misplaced Pages by expanding it. |